StockpollyBeta
Get App
Delisting riskPopularity #4,857
TOVX · AMEX · Biotechnology

Theriva Biologics (TOVX)

Develops stroma-degrading oncolytic viruses for difficult-to-treat solid tumors.

$0.2335
vs last close+0.00 (+1.17%)

In millions of USD, except per-share figures

In millionsQ4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00000000000
Cost of revenue00000000000
Gross profit00000000000
658854134223
Research & development43333323101
221221112122
Selling & marketing00000000000
General & administrative221221112122
Other expenses00430000000
Operating income−6−5−8−8−4−4−13−4−2−2−3
00000000000
Interest income00000000000
Other non-operating income00−4−30000000
Income before tax−6−5−8−8−4−4−13−4−2−2−3
Income tax expense00000000000
Net income from continuing operations−5−5−8−8−4−4−13−4−2−2−3
Net income−5−5−8−8−4−4−13−4−2−2−3
EPS, basic−$8.00−$7.53−$10.75−$6.81−$4.26−$1.55−$1.93−$0.45−$0.10−$0.05−$0.07
EPS, diluted−$8.00−$7.53−$10.72−$6.81−$1.60−$1.55−$1.93−$0.45−$0.10−$0.05−$0.07
Weighted average shares, basic111113710124146
Weighted average shares, diluted111113710124146
EBITDA−6−5−4−5−4−4−13−4−2−2−3
Depreciation & amortization00000000000
EBIT−6−5−4−5−4−4−13−4−2−2−3